Numerical Experiments Sample Clauses

Numerical Experiments. Zy(k + 1) + 1 Ly(k) − xy(k + 1) , where Zy(k) = Z µˆy(k), Gˆy k , and we have used the Minkowski sum of zonotopes as per Sec. III-A. We leave alternative methods of approximating continuous time to future work. For example, one could compute the convex hull between timesteps with constrained zonotopes [45], [50], but the resulting numerical representations are typically large. One could also apply standard zonotope reachability methods [40], [43], though the resulting set representations may not be differentiable.
AutoNDA by SimpleDocs
Numerical Experiments. ‌ To test the method, we generate a 2D image of the size 128 by 128 and assume that the object is made up of three simulated materials that arise in polyenergetic image reconstruction – adipose, air and bones. For bones, we use the main component, cal- cium, to represent it. One application of polyenergetic image reconstruction is breast imaging, which requires low dose radiation for patients. To realize this application, we generate an energy spectrum with potential 26 keV with the help of function “spek- trSpectrum” [53]. We also select a low radiation dose of 1e5 total photons for the x-ray energy spectrum. The corresponding spectrum is shown in Figure 3.1. From Figure 3.1, we can find that the photon flux density is above zero when the energy is between 3 kev and 28 kev. Based on this observation, the discrete energies for the simulated source x-xxx xxxx are chosen from 3 keV to 28 keV, with an interval of 1 keV. Photon flux density The plots of linear attenuation coefficients to materials adipose, air and calcium are shown in Figure 3.2. In Figure 3.2, the red, blue and black curves represent Adipose Air Calcium 105 Linear attenuation coefficient 100 Figure 3.2: The linear attenuation curves for adipose (red), air (blue) and calcium (black). adipose tissue, air and calcium, respectively, and the xxxx patch corresponds to the area of energy flux that is not equivalent to zero. From Figure 3.2, we can see that the curvatures of air and adipose are similar, while the curve of calcium has a K-edge [52]. The similarity of curvatures between adipose and air might cause the collinearity of linear attenuation coefficient matrix C and so as the ill-conditioning of Hessian, while the K-edge might result in difficulty for reconstruction. The simulations of the true object, shown in Figure 3.3, contain four distinct regions: 100% adipose, 0% air, 0% calcium; 0% adipose, 100% air, 0% calcium; 0% adipose, 0% air, 100% calcium; 50% adipose, 50% air, 0% calcium1. In Figure 3.3, the 1We actually tested many different combinations of mixed materials, for example, 20% adipose, 60% air and 20% calcium. The results are are very similar to the one case considered in this experiment, thus to conserve space, we omit the results. yellow color represents regions that contain 100% of the corresponding material, the turquoise color indicates regions that contain 50% of the adipose and air materials, the blue color indicates that the corresponding material does not exist in this ...
Numerical Experiments. ‌ To test the preconditioners and the optimization method, we generate a 2D image of the size 128 by 128 as the object. We also assume that this object is made up of two materials, plexiglass and polyvinyl chloride (PVC). Thus we can obtain 2 material maps corresponding to the weights of these two materials. The original material maps are shown in Figure 4.2. In Figure 4.2, the yellow color represents that it has the corresponding material in this area, while the blue color shows that it does not have the corresponding material in this area. Therefore, we can see that the object is a circle and both materials are distributed inside this circle. Inside this circle, plexiglass dominates most areas except three dots occupied by PVC. We can also 0.9 0.9 0.8 0.8 0.7 0.7 0.6 0.6 0.5 0.5 0.4 0.4 0.3 0.3 0.2 0.2 0.1 0.1 0 0 see that the images corresponding to these two materials compensate each other and they are completely separable. The goal of this numerical experiment is to reconstruct these two images such that different material maps present the corresponding material compositions.
Numerical Experiments. ‌ It is well known that the image deblurring problem requires regularization to stabilize the inversion process when there is noise in y and/or in A. Note that even if the data y has no noise (which is highly unlikely in any real problem), because we use only an approximation of the true boundary ele- ments (e.g, with AZ, AP , AR, AA, or AS), there is effectively noise in A. For the numerical results reported in this section we use standard Tikhonov regularization [25, 33, 36, 68], min }y AXx}2 α}x}2( , where AX is one of AZ, AP , AR, AA, or AS. Our implementation can be ob- tained from RestoreTools1 patched with synthetic boundary conditions mod- ification2 , or Python RestoreTools (PYRET)3. The following experiments are done with the function HyBR (hybrid bidiagonalization regularization) [13, 14], which implements a modified version of LSQR [56], in Restore- Tools. If the true image is known (as we do in our simulations) HyBR can easily compute Tikhonov solutions with optimal regularization parameters. RestoreTools also facilitates the implementation by providing functions to efficiently implement matrix-vector multiplications. In our first set of experiments, we use the “Xxxxxxx” image (Figure 2.3) as the main test image. The following 4 cases are considered: • Gaussian blur (Section 2.4.1) • diagonal motion blur (Section 2.4.2) • Gaussian blur with additive Gaussian noise (Section 2.4.3) • diagonal motion blur with additive Gaussian noise (Section 2.4.4) 1http://xxx.xxxxxx.xxxxx.xxx/~{}xxxx/RestoreTools 2http://xxx.xxxxxx.xxxxx.xxx/~{}yfan/SyntheticBC/SyntheticBcPatch.tgz 3http://xxx.xxxxxx.xxxxx.xxx/~{}yfan/PYRET‌ • DCT based preconditioning with AR (Section 2.4.5)

Related to Numerical Experiments

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws and national and international guidelines (e.g., ICH, cGCP, cGLP, and cGMP).

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order. (b) The technical evaluation committee may call the responsive bidders for discussion or presentation to facilitate and assess their understanding of the scope of work and its execution. However, the committee shall have sole discretion to call for discussion / presentation. (c) Financial bids of only those bidders who qualify the technical criteria will be opened provided all other requirements are fulfilled. (d) AIIMS Jodhpur shall have right to accept or reject any or all tenders without assigning any reasons thereof.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Evaluation Cycle Goal Setting and Development of the Educator Plan A) Every Educator has an Educator Plan that includes, but is not limited to, one goal related to the improvement of practice; one goal for the improvement of student learning. The Plan also outlines actions the Educator must take to attain the goals established in the Plan and benchmarks to assess progress. Goals may be developed by individual Educators, by the Evaluator, or by teams, departments, or groups of Educators who have the similar roles and/or responsibilities. See Sections 15-19 for more on Educator Plans. B) To determine the goals to be included in the Educator Plan, the Evaluator reviews the goals the Educator has proposed in the Self-Assessment, using evidence of Educator performance and impact on student learning, growth and achievement based on the Educator’s self-assessment and other sources that Evaluator shares with the Educator. The process for determining the Educator’s impact on student learning, growth and achievement will be determined after ESE issues guidance on this matter. See #22, below. C) Educator Plan Development Meetings shall be conducted as follows: i) Educators in the same school may meet with the Evaluator in teams and/or individually at the end of the previous evaluation cycle or by October 15th of the next academic year to develop their Educator Plan. Educators shall not be expected to meet during the summer hiatus. ii) For those Educators new to the school, the meeting with the Evaluator to establish the Educator Plan must occur by October 15th or within six weeks of the start of their assignment in that school iii) The Evaluator shall meet individually with Educators with PTS and ratings of needs improvement or unsatisfactory to develop professional practice goal(s) that must address specific standards and indicators identified for improvement. In addition, the goals may address shared grade level or subject matter goals. D) The Evaluator completes the Educator Plan by November 1st. The Educator shall sign the Educator Plan within 5 school days of its receipt and may include a written response. The Educator’s signature indicates that the Educator received the plan in a timely fashion. The signature does not indicate agreement or disagreement with its contents. The Evaluator retains final authority over the content of the Educator’s Plan.

  • FTE The term “

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Final Evaluation IC must submit a final report and a project evaluation to the Arts Commission within thirty (30) days after the completion of the Services. Any and all unexpended funds from IC must be returned to City no later than sixty (60) days after the completion of the Services.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!